IL-6, His, Cynomolgus

IL-6, His, Cynomolgus

IL-6 (Interleukin-6) is a pleiotropic cytokine that acts in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression.Interleukin 6 has been shown to interact with interleukin-6 receptor and glycoprotein.
Z04846
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
IL-6 (Ala28-Met212)
Accession # P79341		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized IL-6, His, Cynomolgus at 5μg/ml (100μl/well) on the plate can bind Human IL­6 R alpha, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 22.06 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background IL-6 (Interleukin-6) is a pleiotropic cytokine that acts in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression.Interleukin 6 has been shown to interact with interleukin-6 receptor and glycoprotein.
Synonyms IFN-beta-2; IL6; IL-6; BSF-2; CDF; MGI-2A; Interleukin-6; HSF; IFNB2; HGF;IFN-β-2

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.